BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 17, 2007
 |  BioCentury  |  Emerging Company Profile

Mimetogen: An eye for neuroprotection

Mimetogen Pharmaceuticals Inc. believes it is the first company attempting to treat glaucoma and other degenerative ophthalmic diseases through neuroprotection, an approach it expects would complement existing drugs.

The company's lead compound mimics the pro-survival effects that nerve growth factor (NGF) has on retinal cells. A second program targets a neurotoxic protein that is up-regulated in response to high intraocular pressure and is a novel target in the pathology of vision-impairing cell loss.

The loss of vision as glaucoma progresses is caused by abnormal loss of retinal ganglion cells (RGCs). What causes the rapid loss of these cells is not well understood, though one known factor is increased intraocular pressure (IOP). Decreasing abnormally high IOP is the goal of all approved glaucoma therapeutics, including adrenergic alpha receptor...

Read the full 628 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >